1035 related articles for article (PubMed ID: 23197272)
1. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry.
Beyer-Westendorf J; Lützner J; Donath L; Radke OC; Kuhlisch E; Hartmann A; Weiss N; Werth S
J Thromb Haemost; 2012 Oct; 10(10):2045-52. PubMed ID: 22882706
[TBL] [Abstract][Full Text] [Related]
3. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty.
Jameson SS; Rymaszewska M; Hui AC; James P; Serrano-Pedraza I; Muller SD
J Bone Joint Surg Am; 2012 Sep; 94(17):1554-8. PubMed ID: 22832942
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban: new drug. After hip or knee replacement surgery: LMWH is safer.
Prescrire Int; 2009 Aug; 18(102):151-3. PubMed ID: 19743567
[TBL] [Abstract][Full Text] [Related]
5. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Huisman MV; Quinlan DJ; Dahl OE; Schulman S
Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of rivaroxaban versus low-molecular-weight heparin therapy in patients with lower limb fractures.
Long A; Zhang L; Zhang Y; Jiang B; Mao Z; Li H; Zhang S; Xie Z; Tang P
J Thromb Thrombolysis; 2014 Oct; 38(3):299-305. PubMed ID: 24402194
[TBL] [Abstract][Full Text] [Related]
7. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment.
Turpie AG; Haas S; Kreutz R; Mantovani LG; Pattanayak CW; Holberg G; Jamal W; Schmidt A; van Eickels M; Lassen MR
Thromb Haemost; 2014 Jan; 111(1):94-102. PubMed ID: 24154549
[TBL] [Abstract][Full Text] [Related]
8. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
[TBL] [Abstract][Full Text] [Related]
9. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
10. A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery.
Abad JI; Gómez-Outes A; Martínez-González J; Rocha E;
Arch Orthop Trauma Surg; 2007 Oct; 127(8):665-70. PubMed ID: 17089172
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry.
Donath L; Lützner J; Werth S; Kuhlisch E; Hartmann A; Günther KP; Weiss N; Beyer-Westendorf J
Br J Clin Pharmacol; 2012 Dec; 74(6):947-58. PubMed ID: 22515679
[TBL] [Abstract][Full Text] [Related]
12. Initiation of rivaroxaban following low molecular weight heparin for thromboprophylaxis after total joint replacement: the Safe, Simple Transitions (SST) study.
Mills RM; Berkowitz RD; Damaraju CV; Jennings LK; Wildgoose P
Thromb Res; 2012 Nov; 130(5):709-15. PubMed ID: 22857800
[TBL] [Abstract][Full Text] [Related]
13. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
15. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
Colwell C; Mouret P
Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
Fisher WD; Eriksson BI; Bauer KA; Borris L; Dahl OE; Gent M; Haas S; Homering M; Huisman MV; Kakkar AK; Kälebo P; Kwong LM; Misselwitz F; Turpie AG
Thromb Haemost; 2007 Jun; 97(6):931-7. PubMed ID: 17549294
[TBL] [Abstract][Full Text] [Related]
17. Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study.
Jensen CD; Steval A; Partington PF; Reed MR; Muller SD
J Bone Joint Surg Br; 2011 Jan; 93(1):91-5. PubMed ID: 21196550
[TBL] [Abstract][Full Text] [Related]
18. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
Lu X; Lin J
BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
[TBL] [Abstract][Full Text] [Related]
20. Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis.
Schiff RL; Kahn SR; Shrier I; Strulovitch C; Hammouda W; Cohen E; Zukor D
Chest; 2005 Nov; 128(5):3364-71. PubMed ID: 16304285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
